NCT06561711

Optimization of Minocycline for Helicobacter Pylori Rescue Treatment

Optimization of Minocycline-containing Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Treatment: a Multicentre, Randomized Controlled Trial

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 480 (actual)
• Sponsor: Shanghai Jiao Tong University School of Medicine · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The efficacy of bismuth-containing quadruple therapy with minocycline and metronidazole was not inferior to classical bismuth quadruple therapy for refractory H. pylori infection, though also accompanied with high occurrence of adverse events (55.4%). Optimization of minocycline-based regimen to achieve high eradication rate with fewer adverse events is imperative. This study aimed to compare the efficacy and tolerability of a 14-day bismuth-containing quadruple rescue therapy with different dosage of minocycline and metronidazole compared to classical bismuth quadruple therapy.

Conditions

• Helicobacter Pylori Infection

Interventions

Type	Name	Description
DRUG	Vonoprazan	Potassium competitive acid blocker
DRUG	Bismuth Potassium Citrate	Gastric mucosal protective drug with anti-H. pylori effect
DRUG	Tetracycline,Metronidazole	Antibiotics for H. pylori eradication
DRUG	Minocycline,Metronidazole	Antibiotics for H. pylori eradication

Timeline

• Start date: 2024-08-21
• Primary completion: 2026-02-21
• Completion: 2026-02-21
• First posted: 2024-08-20
• Last updated: 2026-03-25

Locations

4 sites across 1 country: China